Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma

Abstract

Several mutations were identified in the kinase domain of the RET proto-oncogene in patients with multiple endocrine neoplasia (MEN) 2B, familial medullary thyroid carcinoma (FMTC) or sporadic medullary thyroid carcinoma. We introduced seven mutations (glutamic acid 768→aspartic acid (E768D), valine 804→leucine (V804L), alanine 883→phenylalanine (A883F), serine 891→alanine (S891A), methionine 918 →threonine (M918T), alanine 919→proline (A919P) and E768D/A919P) into the short and long isoforms of RET cDNA and transfected the mutant cDNAs into NIH3T3 cells. The transforming activity of the long isoform of Ret with each mutation was much higher that that of its short isoform. Based on the levels of the transforming activity, these mutant RET genes were classified into two groups; a group with high transforming activity (A883F, M918T and E768D/A919P) and a group with low transforming activity (E768D, V804L, S891A and A919P) (designated high group and low group). Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the A883F or M918T mutation and low group Ret with the E768D, V804L or S891A mutation were associated with the development of MEN 2B and FMTC, respectively. In addition, we found that substitution of phenylalanine for tyrosine 905 present in the kinase domain abolished both transforming and autophosphorylation activities of low group Ret whereas it did not affect the activities of high group Ret.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Arighi E, Alberti L, Torriti F, Ghizzoni S, Rizzetti MG, Pelicci G, Pasini B, Bongarzone I, Piutti C, Pierotti MA and Borrelo MG. . 1997 Oncogene 14: 773–782.

  • Asai N, Iwashita T, Matsuyama M and Takahashi M. . 1995 Mol. Cell. Biol. 15: 1613–1619.

  • Asai N, Murakami H, Iwashita T and Takahashi M. . 1996 J. Biol. Chem. 271: 17644–17649.

  • Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniare J, Lenoir GM and Romeo G. . 1995 Oncogene 10: 2415–2419.

  • Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, Bocciardi R, Mondellini P, Scopsi L, Romeo G, Ponder BAJ and Pierotti MA. . 1995 Oncogene 11: 2419–2427.

  • Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A and Santoro M. . 1997 Cancer Res. 57: 391–395.

  • Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells Jr SA, Goodfellow PJ and Donis-Keller H. . 1994 Proc. Natl. Acad. Sci. USA 91: 1579–1583.

  • Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima T, Lairmore TC, Howe JR, Moley JF, Goodfellow P and Wells Jr SA. . 1993 Hum. Mol. Genet. 2: 851–856.

  • Durick K, Gill GN and Taylor SS. . 1998 Mol. Cell. Biol. 18: 2298–2308.

  • Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD and Ponder BAJ. . 1995 Oncogene 10: 509–513.

  • Eng C, Clayton D, Scuffenecker I, Lenoir G, Gilbert C, Gagel RF, van Amstel HKP, Lips CJM, Nishisho I, Takai S, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thibodeau ST, Lacroix A, Frilling A, Ponder BAJ and Mulligan LM. . 1996 JAMA 276: 1575–1579.

  • Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG and Eng C. . 1997 J. Clin. Endocrinol. Metab. 82: 3902–3904.

  • Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JWM, van Amstel HKP, Romeo G, Lips CJM and Buys CHCM. . 1994 Nature 367: 375–376.

  • Hofstra RMW, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V and Buys CHCM. . 1997 J. Clin. Endocrinol. Metab. 82: 4176–4178.

  • Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G and Takahashi M. . 1997 Cancer Res. 57: 2870–2872.

  • Iwashita T, Asai N, Murakami H and Takahashi M. . 1996 Oncogene 12: 481–487.

  • Lips CJM, Landsvater RM, Hoppener JWM, Geerdink RA, Blijham G, van Veen JMJS, van Gils APG, de Wit MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, van Amstel HKP, van Vroonhoven TJMV and Vroom TM. . 1994 N. Eng. J. Med. 331: 828–835.

  • Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ, Pawson T, Ponder BA and Smith DP. . 1997 Oncogene 14: 763–771.

  • Miyauchi A, Egawa S, Futami H, Kuma K, Obara T and Yamaguchi K. . 1997 Jpn. J. Cancer Res. 88: 527–531.

  • Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A and Ponder BAJ. . 1993 Nature 363: 458–460.

  • Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN and Ponder BAJ. . 1994 Nature Genet. 6: 70–74.

  • Nozaki C, Asai N, Murakami H, Iwashita T, Iwata Y, Horibe K, Klein RD, Rosenthal A and Takahashi M. . 1998 Oncogene 16: 293–299.

  • Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM and Billaud M. . 1997 Oncogene 15: 393–402.

  • Pasini B, Ceccherini I and Romeo G. . 1996 Trends Genetics 12: 138–144.

  • Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL, Rudkin BB, Lenoir GM and Billaud M. . 1997 Oncogene 14: 265–275.

  • Santoro M, Carlomagno F, Romano A, Bottalo DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH and Di Fiore PP. . 1995 Science 267: 381–383.

  • Smith DP, Houghton C and Ponder BAJ. . 1997 Oncogene 15: 1213–1217.

  • Tahira T, Ishizaka Y, Itoh F, Sugimura T and Nagao M. . 1990 Oncogene 5: 97–102.

Download references

Acknowledgements

We are grateful to K Imaizumi, J Aoki, K Uchiyama and M Kozuka for their technical assistance. This work was supported in part by grants-in-aid for COE research, scientific research and cancer research from the Ministry of Education, Science, Sports and Culture of Japan and by grants from the Cell Science Research Foundation and the Mitsubishi Foundation.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iwashita, T., Kato, M., Murakami, H. et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18, 3919–3922 (1999). https://doi.org/10.1038/sj.onc.1202742

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202742

Keywords

This article is cited by

Search

Quick links